SOURCES SOUGHT
A -- Bridge ELISA Validation
- Notice Date
- 9/11/2009
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- US Army Space and Missile Defense Command, Deputy Commander, ATTN SMDC-CM-AP, P.O. Box 1500, Huntsville, AL 35807-3801
- ZIP Code
- 35807-3801
- Solicitation Number
- DVC0094-PLAG-09
- Response Due
- 9/21/2009
- Archive Date
- 11/20/2009
- Point of Contact
- Sandra OConnell, 301-619-2895
- E-Mail Address
-
US Army Space and Missile Defense Command, Deputy Commander
(sandra.oconnell@us.army.mil)
- Small Business Set-Aside
- N/A
- Description
- DynPort Vaccine Company LLC, a CSC company (DVC) is the prime systems contractor for the U.S. Department of Defense Joint Vaccine Acquisition Program (JVAP) and is responsible for the advanced development and licensure with the Food and Drug Administration (FDA) of vaccines and other biological products designed to protect against a variety of biological agents. As part of this program, a recombinant vaccine for protection against pneumonic plague is undergoing advanced development by DVC. The antigenic component of this vaccine is a single protein produced from a fusion of the Yersinia pestis genes for the F1 capsular protein and the V virulence protein. The product is currently being investigated in the U.S. under a DVC sponsored IND. As the efficacy of this vaccine cannot be tested in humans, it is essential to develop in vivo and in vitro surrogate assays that are valid predictors of immunity. A Bridge ELISA has been developed to evaluate and quantify immune response Enzyme Linked Immunosorbent Assays (ELISAs) have been developed for measurement of anti-F1, anti-V, and anti-F1V antibodies. These assays are sandwich enzyme immunoassays for the semi-quantitative determination of antibodies in serum to the recombinant vaccine F1V. The assay is considered semi-quantitative because the calibration curve is prepared from purified chicken antibody whereas the assay measures polyclonal antibodies to the vaccine. These 3 bridge-type ELISAs are used to test clinical and nonclinical (nonhuman primate and murine) serum samples. DVC is seeking the technical services for the technology transfer, and validation of the Bridge ELISA. The technical services are also required for the testing of nonclinical and/or clinical sera samples. 1.0OBJECTIVES 1.1Technology Transfer of F1, V, and F1V ELISA analytical methods 1.2Validation of F1, V, and F1V ELISA analytical methods 1.3Testing of clinical and/or nonclinical samples in F1, V, and F1V Bridge ELISA analytical methods We estimate approximately 13,600 ELISAs to be validated during an 18 month to 2 yr. period. Please respond to this Sources Sought with your capabilities/past performance and interest to Jo Ann Brown, Principal Subcontract Administrator, DVC LLC, a CSC company at jbrown253@csc.com Please only contact the person noted above and not the USASMDC office listed in this announcement.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/SMDC/DASG60/DVC0094-PLAG-09/listing.html)
- Place of Performance
- Address: US Army Space and Missile Defense Command, Deputy Commander ATTN SMDC-CM-AP, P.O. Box 1500 Huntsville AL
- Zip Code: 35807-3801
- Zip Code: 35807-3801
- Record
- SN01952323-W 20090913/090912003142-4cbb19a1fa1ca73ccfe1ad5f30fe7256 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |